IL284772A - Anti-variable muc1* antibodies and uses thereof - Google Patents

Anti-variable muc1* antibodies and uses thereof

Info

Publication number
IL284772A
IL284772A IL284772A IL28477221A IL284772A IL 284772 A IL284772 A IL 284772A IL 284772 A IL284772 A IL 284772A IL 28477221 A IL28477221 A IL 28477221A IL 284772 A IL284772 A IL 284772A
Authority
IL
Israel
Prior art keywords
muc1
antibodies against
against variable
variable
antibodies
Prior art date
Application number
IL284772A
Other languages
English (en)
Hebrew (he)
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/019566 external-priority patent/WO2019165421A1/en
Priority claimed from PCT/US2019/021556 external-priority patent/WO2019173815A2/en
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of IL284772A publication Critical patent/IL284772A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL284772A 2019-01-11 2021-07-11 Anti-variable muc1* antibodies and uses thereof IL284772A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962791661P 2019-01-11 2019-01-11
PCT/US2019/019566 WO2019165421A1 (en) 2018-02-26 2019-02-26 Diagnostic methods using anti-muc1* antibodies
PCT/US2019/021556 WO2019173815A2 (en) 2018-03-09 2019-03-11 Method for anti-muc1* car t cell stimulation
PCT/US2020/013410 WO2020146902A2 (en) 2019-01-11 2020-01-13 Anti-variable muc1* antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL284772A true IL284772A (en) 2021-08-31

Family

ID=71521210

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284772A IL284772A (en) 2019-01-11 2021-07-11 Anti-variable muc1* antibodies and uses thereof

Country Status (8)

Country Link
US (1) US12583927B2 (enExample)
EP (1) EP3908603A4 (enExample)
JP (2) JP2022527144A (enExample)
CN (2) CN120484122A (enExample)
AU (1) AU2020205735A1 (enExample)
CA (1) CA3126391A1 (enExample)
IL (1) IL284772A (enExample)
WO (1) WO2020146902A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
EP3759145A4 (en) * 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
CN120484122A (zh) 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
AU2021316042A1 (en) * 2020-07-29 2023-03-30 Minerva Biotechnologies Corporation Anti-variable MUC1* antibodies and uses thereof
EP4210733B1 (en) * 2020-09-04 2024-11-06 Miltenyi Biotec B.V. & Co. KG System for inducible expression of an adapter in immune cells
JP2024541076A (ja) * 2021-11-09 2024-11-06 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞受容体リガンドを特定するためのマイクロ流体共カプセル化デバイス、システム、及び方法
WO2023123195A1 (zh) * 2021-12-30 2023-07-06 深圳市先康达生命科学有限公司 一种目的基因可调控的工程化免疫细胞及其制备方法和应用
CN119317447A (zh) * 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
WO2023220560A1 (en) * 2022-05-09 2023-11-16 Minerva Biotechnologies Corporation Chimeric antigen receptor and il-18 receptor compositions and methods of use therein
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
US20250121088A1 (en) * 2023-10-11 2025-04-17 Minerva Biotechnologies Corporation Anti-muc1* antibody drug complexes and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240390418A1 (en) 1997-09-04 2024-11-28 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
AU3087801A (en) * 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
EP3130607B1 (en) * 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
JP2012034668A (ja) * 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
WO2014028668A2 (en) * 2012-08-14 2014-02-20 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
WO2015116753A1 (en) 2014-01-29 2015-08-06 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
AU2015243948B2 (en) 2014-04-07 2020-10-15 Minerva Biotechnologies Corporation Anti-NME antibody
CN116199790A (zh) * 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
EP3265486A4 (en) * 2015-03-06 2018-11-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
CA3039797A1 (en) 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
US11578115B2 (en) * 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
WO2019104306A1 (en) 2017-11-27 2019-05-31 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and direct use of cleavage enzyme
WO2019124468A1 (ja) 2017-12-24 2019-06-27 ノイルイミューン・バイオテック株式会社 ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
JP7416695B2 (ja) 2017-12-29 2024-01-17 メモリアル スローン－ケタリング キャンサー センター 増強されたキメラ抗原受容体およびその使用
EP3759145A4 (en) * 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
EP3868783A4 (en) 2018-10-19 2022-01-19 Cartexell Inc. ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR THEREOF
WO2020116686A1 (ko) 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도
CN120484122A (zh) 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
CN110903401A (zh) 2019-11-20 2020-03-24 浙江大学 一种靶向cd19的二代嵌合抗原受体及其表达载体与应用
AU2021316042A1 (en) 2020-07-29 2023-03-30 Minerva Biotechnologies Corporation Anti-variable MUC1* antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases

Also Published As

Publication number Publication date
CA3126391A1 (en) 2020-07-16
US12583927B2 (en) 2026-03-24
EP3908603A2 (en) 2021-11-17
JP2022527144A (ja) 2022-05-31
AU2020205735A1 (en) 2021-08-05
CN113853386A (zh) 2021-12-28
JP2025172739A (ja) 2025-11-26
EP3908603A4 (en) 2023-01-11
WO2020146902A2 (en) 2020-07-16
US20220184120A1 (en) 2022-06-16
WO2020146902A3 (en) 2020-08-27
CN120484122A (zh) 2025-08-15

Similar Documents

Publication Publication Date Title
IL284772A (en) Anti-variable muc1* antibodies and uses thereof
IL289354A (en) Anti-cd154 antibodies and uses thereof
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND THEIR USES
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL286717A (en) Immunotherapeutic compositions and use thereof
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
IL269122A (en) Anti-c5 antibodies and uses thereof
SG11202104240TA (en) Cll1-targeting antibody and application thereof
EP3904382A4 (en) ANTI-IL-23P19 ANTIBODIES AND ITS USES
PL3710484T3 (pl) Przeciwciała wiążące ctla-4 i ich zastosowania
EP4071172A4 (en) ANTI-LILRB1 ANTIBODIES AND ITS USES
IL281297A (en) Anti-npr1 antibodies and uses thereof
IL271398A (en) Anti-l1-cam antibodies and uses thereof
EP4025609A4 (en) ANTI-STEAP1 ANTIBODIES AND THEIR USES
IL283875A (en) Anti-il-27 antibodies and uses thereof
EP4188959A4 (en) Anti-variable muc1* antibodies and uses thereof
EP3774888A4 (en) Anti-phf-tau antibodies and uses thereof
PL4036113T3 (pl) Humanizowane przeciwciało anty-il17a i jego zastosowanie
IL276548A (en) Binding antibodies - BCMA and their uses
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
IL291280A (en) Anti-cd371 antibodies and uses thereof
IL291550A (en) Anti-il-27 antibodies and uses thereof
IL288923A (en) Anti-cd47 antibodies and uses thereof
EP3794039A4 (en) PD-1 BINDING ANTIBODIES AND USE
IL280281A (en) Anti-cd40 antibodies and uses thereof